GlassScriptPhysician profile
Alexander C Shaw
NPI 1609367119
$2,402.20
in general payments reported to CMS, 2019-2025
23 companies · $95.57 in 2025
The $95.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.89 · 2021: $315 · 2022: $1,053 · 2023: $742 · 2024: $136 · 2025: $95.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $401.88 | 2021-2024 | |
| Lilly USA, LLC | $327.11 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Preventric Diagnostics, INC. | $225.90 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $164.88 | 2021-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.44 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $103.84 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $81.48 | 2021-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $58.08 | 2021-2022 | |
| Amarin Pharma, INC. | $57.32 | 2022 | |
| Seqirus USA INC | $55.61 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $55.29 | 2019-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $50.72 | 2022 | |
| Xeris Pharmaceuticals, INC. | $47.77 | 2023 | Gvoke Hypopen, Keveyis |
| Idorsia Pharmaceuticals US INC | $38.76 | 2022-2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diabetes Care, INC. | $33.31 | 2022 | |
| Sanofi Pasteur INC. | $22.11 | 2022 | |
| Almatica Pharma LLC | $21.82 | 2022 | |
| Nevro Corp. | $21.18 | 2022 | |
| Astellas Pharma US INC | $19.45 | 2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $13.75 | 2021 | |
| Merck Sharp & Dohme LLC | $12.71 | 2019 | |
| Vistapharm, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.